Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial.

PLoS One · 2014 · PMC4269456 · PMID 25517733

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

360 mg dose administered 3 times, did show a strong trend of higher antibody response, further studies are warranted to examine even higher and more frequent doses in order to establish the best conditions for clinical improvement.

also in 5,725 other papers

showed a trendno p-value reported

Patients who developed anti-TNF antibodies showed a trend toward clinical improvement.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.